For research use only. Not for therapeutic Use.
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation[1].
ARN25068 reduces the extent of tau phosphorylation in Tau0N4R-TM-tGFP U2OS cell line. ARN25068 exhibits IC50 values of 4.17 and 2.17 μM for GSK-3β and FYN in enzymatic radiometric assay, respectively[1].
| Catalog Number | I043895 |
| CAS Number | 2649882-80-2 |
| Synonyms | 2-N-benzyl-4-N-(5-cyclopropyl-1H-pyrazol-3-yl)thieno[3,2-d]pyrimidine-2,4-diamine |
| Molecular Formula | C19H18N6S |
| Purity | ≥95% |
| InChI | InChI=1S/C19H18N6S/c1-2-4-12(5-3-1)11-20-19-21-14-8-9-26-17(14)18(23-19)22-16-10-15(24-25-16)13-6-7-13/h1-5,8-10,13H,6-7,11H2,(H3,20,21,22,23,24,25) |
| InChIKey | TVUWQDLBEOZVOU-UHFFFAOYSA-N |
| SMILES | C1CC1C2=CC(=NN2)NC3=NC(=NC4=C3SC=C4)NCC5=CC=CC=C5 |
| Reference | [1]. Stefania Demuro, et al. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders. Eur J Med Chem. 2022 Feb 5;229:114054. |
